Bicara Therapeutics (BCAX) CFO sells 9,200 shares after exercising options
Rhea-AI Filing Summary
Bicara Therapeutics Inc.’s Chief Financial Officer Hyep Ivan reported a combination of option exercise and share sale. Ivan exercised stock options for 9,200 shares of common stock at an exercise price of $3.7898 per share, then sold 9,200 shares in an open-market transaction at a weighted average price of $20.4221 per share.
The sale was executed on May 21, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on February 13, 2025. Following these transactions, Ivan directly holds 145,355 shares of common stock and retains stock options covering 70,584 shares expiring on August 8, 2033, which vest in sixteen equal quarterly installments following August 8, 2023, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 9,200 shares ($153K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Hyep Ivan
Role
Chief Financial Officer
Sold
9,200 shs ($188K)
Approx. gross sale proceeds
$188K
Approx. exercise cost
$35K
Approx. pre-tax spread
$153K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 9,200 | $0.00 | $0.00 |
| Exercise | Common Stock | 9,200 | $3.7898 | $35K |
| Sale | Common Stock | 9,200 | $20.4221 | $188K |
Holdings After Transaction:
Stock Option (Right to Buy) — 70,584 shares (Direct);
Common Stock — 145,355 shares (Direct)
Footnotes (3)
- F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025.
- F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.25 to $20.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F3. The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Shares sold: 9,200 shares
Sale price: $20.4221 per share
Exercise price: $3.7898 per share
+4 more
7 metrics
Shares sold
9,200 shares
Open-market sale of common stock on May 21, 2026
Sale price
$20.4221 per share
Weighted average sale price for 9,200 shares
Exercise price
$3.7898 per share
Stock option exercise for 9,200 common shares
Shares held after
145,355 shares
Common stock directly owned after transactions
Options remaining
70,584 shares
Underlying common shares remaining under stock options
Rule 10b5-1 plan date
February 13, 2025
Adoption date of trading plan governing the sale
Option expiration
August 8, 2033
Expiration date of the stock option grant
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) reported as a derivative security transaction."
open-market sale financial
"transaction_action is described as an open-market sale of common stock."
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative security financial
"Exercise or conversion of derivative security related to stock options."
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Bicara Therapeutics (BCAX) report for Hyep Ivan?
Bicara Therapeutics’ CFO Hyep Ivan exercised options and sold shares. He exercised options for 9,200 common shares at $3.7898 each, then sold 9,200 shares in the open market at a weighted average price of $20.4221 per share on May 21, 2026.
What stock options did the Bicara Therapeutics (BCAX) CFO exercise in this Form 4?
The CFO exercised stock options covering 9,200 Bicara Therapeutics common shares at an exercise price of $3.7898 per share. These options are part of a grant that vests in sixteen equal quarterly installments following August 8, 2023, subject to his continued service.
What is the vesting schedule for the Bicara Therapeutics (BCAX) CFO’s stock options?
The options underlying these transactions vest in sixteen equal quarterly installments after August 8, 2023. Vesting continues only if the CFO remains in service on each vesting date, and the option grant is scheduled to expire on August 8, 2033, if not fully exercised.